Virtu Financial LLC Purchases New Position in Editas Medicine, Inc. (NASDAQ:EDIT)

Virtu Financial LLC acquired a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 73,886 shares of the company’s stock, valued at approximately $748,000. Virtu Financial LLC owned approximately 0.09% of Editas Medicine at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP grew its stake in shares of Editas Medicine by 40.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,392,396 shares of the company’s stock valued at $24,236,000 after acquiring an additional 690,366 shares in the last quarter. Vanguard Group Inc. grew its stake in Editas Medicine by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 8,536,208 shares of the company’s stock valued at $66,582,000 after purchasing an additional 370,734 shares in the last quarter. International Assets Investment Management LLC increased its holdings in Editas Medicine by 1,183.6% during the 4th quarter. International Assets Investment Management LLC now owns 288,269 shares of the company’s stock worth $28,457,000 after purchasing an additional 265,812 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Editas Medicine by 32.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 688,964 shares of the company’s stock valued at $5,374,000 after purchasing an additional 170,694 shares in the last quarter. Finally, Seven Eight Capital LP purchased a new position in shares of Editas Medicine during the 4th quarter valued at approximately $1,482,000. Hedge funds and other institutional investors own 71.90% of the company’s stock.

Editas Medicine Stock Performance

Shares of EDIT stock opened at $5.06 on Monday. Editas Medicine, Inc. has a 1 year low of $4.91 and a 1 year high of $11.69. The business’s fifty day moving average is $5.64 and its 200-day moving average is $7.68. The stock has a market cap of $416.12 million, a PE ratio of -2.41 and a beta of 2.06.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Wednesday, May 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.13). Editas Medicine had a negative return on equity of 47.34% and a negative net margin of 239.36%. The firm had revenue of $1.10 million for the quarter, compared to analyst estimates of $11.14 million. During the same period in the previous year, the firm earned ($0.71) earnings per share. Editas Medicine’s revenue was down 88.9% on a year-over-year basis. Equities research analysts predict that Editas Medicine, Inc. will post -2.7 earnings per share for the current year.

Analysts Set New Price Targets

EDIT has been the subject of several recent analyst reports. StockNews.com lowered shares of Editas Medicine from a “hold” rating to a “sell” rating in a report on Thursday, May 9th. Evercore ISI lowered their price objective on Editas Medicine from $15.00 to $7.00 and set an “in-line” rating for the company in a report on Thursday, May 30th. JPMorgan Chase & Co. upped their price objective on Editas Medicine from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Tuesday, February 27th. Barclays decreased their target price on Editas Medicine from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Thursday, May 9th. Finally, Morgan Stanley upgraded Editas Medicine from an “underweight” rating to an “equal weight” rating and set a $7.00 price objective on the stock in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $12.90.

Insider Transactions at Editas Medicine

In related news, CEO Gilmore Neil O’neill sold 12,191 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $5.50, for a total transaction of $67,050.50. Following the completion of the sale, the chief executive officer now directly owns 315,279 shares in the company, valued at $1,734,034.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Gilmore Neil O’neill sold 12,191 shares of the company’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $5.50, for a total transaction of $67,050.50. Following the completion of the sale, the chief executive officer now directly owns 315,279 shares of the company’s stock, valued at $1,734,034.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jessica Hopfield purchased 45,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average price of $5.64 per share, with a total value of $253,800.00. Following the transaction, the director now directly owns 67,700 shares in the company, valued at $381,828. The disclosure for this purchase can be found here. Corporate insiders own 1.90% of the company’s stock.

Editas Medicine Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.